TREATMENT AND OUTCOMES OF RHEUMATOID ARTHRITIS PATIENTS WITH HEPATITIS BTreatment and outcomes of rheumatoid arthritis patients with hepatitis b
- Other Titles
- Treatment and outcomes of rheumatoid arthritis patients with hepatitis b
- Authors
- Choi, C. -B.; Sung, Y. -K.; Cho, S. -K.; Yoo, D. -H.; Lee, S. -S.; Lee, J.; Kim, J.; Lee, H. -S.; Kim, T. -H.; Yoon, B. Y.; Yoo, W. -H.; Choe, J. -Y.; Lee, S. -H.; Shim, S. -C.; Chung, W. -T.; Hong, S. -J.; Lee, C. K.; Koh, E.; Jun, J. -B.; Bang, S. -Y.; Kim, S. -K.; Cha, H. -S.; Won, S.; Bae, S. -C.
- Issue Date
- Jun-2013
- Publisher
- BMJ PUBLISHING GROUP
- Citation
- ANNALS OF THE RHEUMATIC DISEASES, v.72, no.suppl.3, pp.A851.4 - A852
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF THE RHEUMATIC DISEASES
- Volume
- 72
- Number
- suppl.3
- Start Page
- A851.4
- End Page
- A852
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/26714
- DOI
- 10.1136/annrheumdis-2013-eular.2536
- ISSN
- 0003-4967
- Abstract
- Background Treatment of rheumatoid arthritis (RA) patients with hepatitis B carries risk for reactivation of hepatitis B and drug-related hepatotoxicity.
Objectives We investigated the impact of treatment for RA in patients with hepatitis B.
Methods Patients enrolled in KORONA (Korean Observational Study Network for Arthritis) with 1-year follow up assessment with data on hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) status were included in the analysis. Patient characteristics (age, sex, disease duration, delay in diagnosis, alcohol intake), disease outcome measures (DAS28, fatigue, sleep, HAQ, EQ-5D, radiographic damage, surgery), medications, and adverse events were assessed. Multiple logistic regression was used to analyze the predicting factors for liver function abnormalities.
Results : A total of 871 patients were assessed. The number of HBsAg-positive and HBcAb-positive patients were 48 (5.5%) and 372 (42.7%), respectively. HBcAb-positive groups were significantly older (56.3 ± 10.8 vs 52.5 ± 9.0 in HBsAg-positive group and 51.3 ± 13.3 in negative group, p<0.01) and had longer disease duration (8.4 ± 7.7 vs 7.7 ± 6.0 in HBsAg-positive group and 7.8 ± 7.2 in negative-group, p=0.46). There was no significant difference in disease outcome measures between the groups, except for significantly increased radiographic damage in HBcAb group (79.6% vs 70.8% in HBsAg-positive group and 72.5% in negative group, p=0.048). Methotrexate and biologics use were significantly lower in HBsAg-positive group, while hydroxychloroquine, sulfasalazine, tacrolimus, and steroids use were significantly higher. HBsAg-positive group had significantly more adverse events (52.1%) compared to HBcAb-positive group (29.3%) and negative group (32.8%). HBsAg-positivity and HBcAb-positivity was not associated with significant increase in liver function abnormalities in the study population in multiple logistic regression analysis (OR (95%CI), 2.2 (0.7-7.4) and 0.8 (0.4-1.7), respectively).
Conclusions HBsAg-positive patients were more frequently treated with steroids and less with methotrexate, but there was no significant difference in disease outcome. HBsAg-positive patients had more adverse events, but it did not show significant association with developing liver function abnormality.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/26714)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.